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Insulin signaling is key to the etiology ofmetabolic syndrome.Recentwork (Luan et al., 2009) uncovers a role for
b-arrestin,previouslyknowntocontrolGPCRdesensitization, in insulin signaling. Inmousemodels,b-arrestin-2
controls whole-body insulin action by regulating assembly of a complex containing insulin receptor, c-Src,
and Akt.
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PreviewsInsulin resistance or impaired insulin
action in muscle, fat, and liver is one of
the earliest detectable defects associ-
ated with a range of metabolic diseases
including type 2 diabetes (T2D). Over-
eating, or a lack of exercise coupled with
obesity have been implicated as major
factors contributing to insulin resistance.
At the cellular level, a range of abnormali-
ties (including ER stress, oxidative stress,
mitochondrial defects, intracellular lipids,
or inflammation) have been experimen-
tally linked to insulin resistance. However,
the molecular basis for insulin resistance
remains controversial in that some studies
indicate a primary role for a signaling
defect at insulin receptor substrate 1
(IRS1) leading to reduced Akt activation
(reviewed in Taniguchi et al., 2006), while
other studies suggest otherwise (Kim
et al., 1999; Hoehn et al., 2008). In a recent
issue of Nature, Luan et al. (2009) now
provide evidence for yet another insulin
action rebel: b-arrestin-2.
b-arrestin-2 was originally identified as
a mediator of b-adrenergic receptor endo-
cytosis, leading to attenuation of b-adren-
ergic signaling. However, subsequent
studies have revealed a broad tissue
distribution and an array of interacting
molecules, suggesting that b-arrestins
play a general role in many signaling
pathways. For example, they regulate
the desensitization and downregulation
of many G protein-coupled receptors
(GPCRs) (DeWire et al., 2007). They also
act as a scaffold for key signaling mole-
cules including the tyrosine kinase c-Src;
receptors for insulin, IGF1 and PDGF; and
Ser/Thr kinases including Akt, Raf, ERK,
and JNK (Hupfeld and Olefsky, 2007).
Luan et al. (2009) begin to integrate
some of these disparate attributes of
b-arrestin function in the context of insulinaction in muscle and liver. They show that
b-arrestin-2 expression in muscle and
liver, but not fat, is reduced by 50% in
insulin-resistant animal models and in
liver from a small cohort of T2D humans;
b-arrestin-1 expression was normal.
b-arrestin-2 / mice were insulin re-
sistant; results from b-arrestin-2 haploin-
sufficient animals were unfortunately not
described—these might have provided
a direct corollary of the initial physiolog-
ical data. Regardless, 2-fold overexpres-
sion of b-arrestin-2 in mice led to
increased insulin sensitivity, supporting
the thesis that b-arrestin-2 expression is
correlated with insulin action.
How might b-arrestin-2 modulate
insulin sensitivity? In an extensive series
of experiments, Luan et al. first showed
that while signaling to PI3 kinase was
normal in livers from the b-arrestin-2 /
mice, the next step in the cascade, Akt
activation, was impaired. Luan et al.
showed that b-arrestin-2 acts as a scaf-
fold for the insulin-dependent assembly
of an insulin receptor/c-Src/Akt complex
leading to c-Src-mediated phosphoryla-
tion of Akt at Tyr315/Tyr326. Insulin-
dependent Akt tyrosine phosphorylation
was defective in b-arrestin-2 / mice,
concomitant with reduced phosphoryla-
tion of Akt at Thr308 and Ser473, the
two sites that are essential for full Akt
activation. The converse was observed in
b-arrestin-2 overexpressing mice. Thus,
Luan et al. suggest that, in addition to the
IRS-1/PI3K pathway, a second pathway
downstream of the insulin receptor is
required for full Akt activation (see
Figure 1B). A disruption in the formation
of this complex, due to reduced
b-arrestin-2 expression, leads to impaired
Akt activation followed by insulin resis-
tance. This is potentially very exciting inCell Metabolisview of the major role that Akt plays in
numerousbiological processes.However,
some aspects of the study by Luan et al.
seem to require clarification. The first
involves the role of tyrosine phosphoryla-
tion in Akt activation and the second
involves the link between b-arrestin-2
mediated Akt regulation and whole-body
insulin resistance, which are discussed
below.
With regard to tyrosine phosphorylation
of Akt, the conventional view is that full
activation of Akt in response to insulin is
mediated via phosphorylation at Thr308
and Ser473 by PDK1 and PDK2 (see
Figure 1A). However, several studies
have shown that Akt is also phosphory-
lated at Tyr315, Tyr326, and Tyr474 and
that this also plays a key role in kinase acti-
vation (Chen et al., 2001; Conus et al.,
2002). However, in these studies, there
was no evidence that Akt tyrosine phos-
phorylation regulated PDK-mediated
phosphorylation of Akt at Thr308 and
Ser473. Rather, inhibition of Akt tyrosine
phosphorylation impaired Akt activity
independently of PDK function via an ill-
defined mechanism (Chen et al., 2001;
Conus et al., 2002). In contrast to these
studies, Luan et al. show that tyrosine
phosphorylation of Akt at Tyr315/326
plays a major role in regulating Thr308/
Ser473 phosphorylation (see Figure 1B).
In b-arrestin-2 / mice and under other
conditions where c-Src function was
inhibited, they observed almost complete
inhibition of insulin-dependent phos-
phorylation of Akt at both Thr308 and
Ser473, whereas the converse was found
in b-arrestin-2-overexpressing animals.
Thus, while the studies of Luan et al.
provide a more plausible mechanism as
to howAkt tyrosine phosphorylationmight
regulate kinase activity, the discrepancym 9, March 4, 2009 ª2009 Elsevier Inc. 213
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Previewswith previous studies needs to be
resolved. These studies also need to be
interpreted in light of observations that
selective targeting of Akt to the plasma
membrane in the absence of any stimulus
that would likely activate c-Src kinase,
results in robust phosphorylation of Akt
at Thr308/Ser473 and kinase activity (Ng
et al., 2008).
The demonstration of an insulin-regu-
lated complex involving the insulin
receptor, c-Src, Akt, and b-arrestin-2 is
extremely exciting and has important
implications for our understanding of
insulin action. While the physiological
data in animal models and the signaling
data were compelling in the Luan et al.
study, the linkagebetween theseobserva-
tions is still not completely clear. For
example, despite having normal food
intake, b-arrestin-2 / mice had incre-
ased body weight on a high-fat diet while
b-arrestin-2-overexpressing animals had
reduced body weight. Assuming that
these changes were accounted for by
adiposity (these data were not reported),
one plausible explanation is that the differ-
ence in insulin sensitivity in these animals
is a simple consequence of altered body
weight per se rather than a direct conse-
quence of altered insulin signaling in
muscle and liver as a function of modified
b-arrestin-2 expression. Interestingly,
previous studies have shown that
b-arrestin-2 / mice are hypoactive
(Bohn et al., 2003) with defective tempera-
ture control (Bohn et al., 1999). Both these
traits likely contribute to increased body
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Figure 1. Models of Akt Activation
(A) The conventional model for regulation of Akt by insulin involves tyrosine phosphorylation of IRS1, which
recruits PI3K to the plasma membrane, where it generates PIP3. PIP3 acts as a docking site for PDKs and
Akt leading to the phosphorylation of Akt on Thr308 and Ser473, concomitant with its activation.
(B) Luan et al. propose a two-stepmodel for Akt activation whereby insulin triggers the assembly of a tetra-
meric complex comprising insulin receptor, b-arrestin-2, c-Src, and Akt. This allows c-Src to phosphory-
late Akt on Tyr315 and Tyr326 (step 1), and this step is somehow required (step 2) for phosphorylation of
Akt at Thr308 and Ser473 (step 3) and its full activation. Luan et al. showed that impairment of c-Src func-
tion using PP2 or deletion of b-arrestin-2 inhibited tyrosine phosphorylation of Akt and its activation.214 Cell Metabolism 9, March 4, 2009 ª2009 Elsevier Inc.weight, particularly if they areexacerbated
upon high-fat feeding. Because fat accu-
mulation leads to insulin resistance, more
work is required to justify the link between
b-arrestin-2-mediated tyrosine phosphor-
ylation of Akt and whole-body insulin
action. Simultaneous analysis of insulin
signaling and insulin action in isolated
muscle and primary hepatocytes from
wild-type and b-arrestin-2 / mice
would clarify matters, as well as more
extensive studies of activity and thermo-
genesis in both chow and fat-fed animals.
Despite the lack of firm evidence linking
these parameters, the identification of
a second insulin-regulated pathway
involving Akt tyrosine phosphorylation is
potentially very important, but as is often
the case with challenging new ideas,
more workwill be required to both confirm
and conquer its mechanistic architecture.
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